Harnessing big data to characterize immune-related adverse events
Immune-checkpoint inhibitors (ICIs) have transformed patient care in oncology but are
associated with a unique spectrum of organ-specific inflammatory toxicities known as …
associated with a unique spectrum of organ-specific inflammatory toxicities known as …
Effectiveness and safety of immune checkpoint inhibitors for patients with advanced non small-cell lung cancer in real-world: review and meta-analysis
M Mencoboni, M Ceppi, M Bruzzone, P Taveggia… - Cancers, 2021 - mdpi.com
Simple Summary The benefit of programmed death-1/programmed death ligand-1 (PD-1/PD-
L1) immunotherapy, particularly of nivolumab, pembrolizumab and atezolizumab, in the …
L1) immunotherapy, particularly of nivolumab, pembrolizumab and atezolizumab, in the …
Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world …
PURPOSE Commonly used first-line (1L) treatments for mantle cell lymphoma include high-
dose cytarabine-based induction followed by autologous stem-cell transplant (ASCT) for …
dose cytarabine-based induction followed by autologous stem-cell transplant (ASCT) for …
Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
V Velcheti, X Hu, B Piperdi, T Burke - Scientific reports, 2021 - nature.com
Evidence from real-world clinical settings is lacking with regard to first-line immunotherapy
plus chemotherapy for the treatment of non-small cell lung cancer (NSCLC). Our aim was to …
plus chemotherapy for the treatment of non-small cell lung cancer (NSCLC). Our aim was to …
Clinical validation of a machine-learning–derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer
Abstract Purpose: FOLFOX, FOLFIRI, or FOLFOXIRI chemotherapy with bevacizumab is
considered standard first-line treatment option for patients with metastatic colorectal cancer …
considered standard first-line treatment option for patients with metastatic colorectal cancer …
Methods for external control groups for single arm trials or long‐term uncontrolled extensions to randomized clinical trials
JD Seeger, KJ Davis, MR Iannacone… - … and Drug Safety, 2020 - Wiley Online Library
Purpose Clinical trials compare outcomes among patients receiving study treatment with
comparators drawn from the same source. These internal controls are missing in single arm …
comparators drawn from the same source. These internal controls are missing in single arm …
A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell …
KL Ayers, M Ma, G Debussche, D Corrigan… - BMC cancer, 2021 - Springer
Abstract Background Immune checkpoint inhibitors (ICIs) have been incorporated into
various clinical oncology guidelines for systemic treatment of advanced non-small cell lung …
various clinical oncology guidelines for systemic treatment of advanced non-small cell lung …
[HTML][HTML] Efficacy of cationic amphiphilic antihistamines on outcomes of patients treated with immune checkpoint inhibitors
Background Cationic amphiphilic antihistamines have been shown to improve patient
outcomes in immunogenic tumours, but whether they can augment and improve response to …
outcomes in immunogenic tumours, but whether they can augment and improve response to …
Association of sociodemographic factors with immunotherapy receipt for metastatic melanoma in the US
Importance Strides to improve survival in metastatic melanoma have been made with the
use of immunotherapeutic agents in the form of immune checkpoint inhibitors. Objective To …
use of immunotherapeutic agents in the form of immune checkpoint inhibitors. Objective To …
Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a …
E Nadler, B Arondekar, KM Aguilar, J Zhou… - Journal of Cancer …, 2021 - Springer
Purpose Treatments for advanced non-small cell lung cancer (NSCLC) have evolved to
include targeted and immuno-oncology therapies, which have demonstrated clinical benefits …
include targeted and immuno-oncology therapies, which have demonstrated clinical benefits …